Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from Syntara
- Further significant results from SNT-4728 iRBD Phase 2 trial
- Syntara expands SNT-9465 skin scarring study
- Appendix 4E and Annual Report
- Encouraging SNT-4728 Phase 2 iRBD results
- Results of Share Purchase Plan
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara